Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (PRIMED-001)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02993991 |
|
Recruitment Status :
Withdrawn
(The study has been terminated due to a change in internal prioritization and not due to any safety concerns.)
First Posted : December 15, 2016
Last Update Posted : December 29, 2017
|
Sponsor:
University Health Network, Toronto
Collaborators:
Mirati Therapeutics Inc.
AstraZeneca
Information provided by (Responsible Party):
University Health Network, Toronto
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Actual Primary Completion Date : | December 21, 2017 |
| Actual Study Completion Date : | December 21, 2017 |